Raludotatug Deruxtecan (R-DXd), a CDH6-targeted ADC with the Topoisomerase 1 inhibitor DXd, is currently in clinical trials for advanced ovarian and renal cancers, and exhibits promising clinical activity in ovarian cancer patients without neurologic toxicities [16]. The gene discussed is CDH6; the disease is renal carcinoma.